Endometriosis — RepurpOS | OpenSourceMedicine

Disease overview

Alterations

116

Molecular (A)

100

Clinical (B–E)

Direct drugs

Via biomarker

387

Natural agents

Natural products

Merged ranked

477

With trial/literature evidence

Sources: Open Targets, HPO, ClinicalTrials.gov, DGIdb, ChEMBL, PubMed Literature, Examine.com, PubMed NP Literature · Pipeline phase 7 · Updated 2026-07-06

Remission & chronicity

Spontaneous remission

Endometriosis lesions may partially regress after menopause; spontaneous resolution of symptoms rare; recurrence rate after surgery 20-40% at 2 years and 50-60% at 5 years

Best-intervention remission

Excision surgery achieves pain relief in 60-80% at 6 months but 50% recurrence at 5 years; GnRH agonists + add-back therapy: 70-90% pain reduction but oestrogen-deprivation side effects; combined OCP: 50-60% pain reduction; elagolix (Orilissa): 43% reduction in dysmenorrhoea vs placebo (ELARIS EM-I)

Drug-free remission

—

Relapse after remission

—

Chronicity

—

Gap size

Very large — diagnostic delay averages 7-10 years from symptom onset; no disease-modifying treatment; high recurrence after surgery

Primary barrier

biological + practice

Barrier detail: Diagnostic delay of 7-10 years is the largest modifiable factor; endometriosis dismissed as 'normal period pain'; no non-surgical diagnostic test; all medical treatments are suppressive not curative; recurrence after surgery is universal without continued medical suppression

Last SoC change: 2023 — linzagolix (Yselty, GnRH antagonist) approved in Europe; 2021 relugolix combination (Myfembree) FDA approved; elagolix (Orilissa) 2018; GnRH agonists standard since 1980s; excision surgery approach unchanged for decades

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: MONDO: MONDO:0005133

Right to Try Relevance

Eligibility: This disease meets the federal and state right-to-try legal standard (21 U.S.C. § 360bbb-0a and Montana SB 535): it lacks disease-modifying therapy with indication-specific FDA approval. Patients with Endometriosis may be eligible to access investigational therapies outside of clinical trials under right-to-try frameworks.

Investigational Agents

Phase 3: 27, Phase 2: 13

Most Advanced Phase

Phase 3

Highest dev. stage

Gene Targets

116

Actionable

Pipeline Compounds (Top 6)

Asoprisnil, Cannabidiol, Choriogonadotropin Alfa, Cyproterone Acetate, Degarelix, Dydrogesterone

Legal Standard: Right-to-try requires the disease lacks "adequate approved therapy for that specific disease" (not symptom-management drugs). This distinction means a disease with antidepressants available still qualifies if no FDA approval exists for THAT disease indication.

View Right-to-Try Compendium

Alterations

Showing 80 of 116 · Types A (molecular) through E (functional)

Name	Type	Subtype	Direction	Frequency	Evidence	Sources	Links
ABO ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Molecular	Gene	—	—	Emerging	Open Targets	Ensembl Open Targets
AKT1 AKT serine/threonine kinase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AMER1 APC membrane recruitment protein 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AMH dosage	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
AMH level	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
APOH apolipoprotein H	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AR androgen receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ARHGAP26 Rho GTPase activating protein 26	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ARID1A AT-rich interaction domain 1A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ARID2 AT-rich interaction domain 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ARL14EP ARF like GTPase 14 effector protein	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AUTS2 activator of transcription and developmental regulator AUTS2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Acceptability of menstrual health and endometriosis education (quantitative)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
CARD11 caspase recruitment domain family member 11	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CCDC170 coiled-coil domain containing 170	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CD109 CD109 molecule	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDC42 cell division cycle 42	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDKN2B cyclin dependent kinase inhibitor 2B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CEP112 centrosomal protein 112	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CNR1 cannabinoid receptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CREBBP CREB binding lysine acetyltransferase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CTCF CCCTC-binding factor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CTNNB1 catenin beta 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Complication rate	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
DDR2 discoidin domain receptor tyrosine kinase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DENND1B DENN domain containing 1B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DIAPH3 diaphanous related formin 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DISC1 DISC1 scaffold protein	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DLEU7 deleted in lymphocytic leukemia 7	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DMRTA1 DMRT like family A1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DNM3 dynamin 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
EEFSEC eukaryotic elongation factor, selenocysteine-tRNA specific	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ESR1 estrogen receptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ETAA1 ETAA1 activator of ATR kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ETV6 ETS variant transcription factor 6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Endometrioma recurrence	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Evaluation of the ovarian reserve by ultrasound by CFA	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
FGD6 FYVE, RhoGEF and PH domain containing 6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FGFR4 fibroblast growth factor receptor 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FOXP1 forkhead box P1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FRMD7 FERM domain containing 7	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FSHB follicle stimulating hormone subunit beta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FSHR follicle stimulating hormone receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GDAP1 ganglioside induced differentiation associated protein 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GNRH1 gonadotropin releasing hormone 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GNRHR gonadotropin releasing hormone receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GPNMB glycoprotein nmb	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GREB1 growth regulating estrogen receptor binding 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GRIN1 glutamate ionotropic receptor NMDA type subunit 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HEY2 hes related family bHLH transcription factor with YRPW motif 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HNF1A HNF1 homeobox A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HOXA10 homeobox A10	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ID4 inhibitor of DNA binding 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL1A interleukin 1 alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL7R interleukin 7 receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Investigation of the role of Relaxin, Matrix Metalloproteinase-2 and Interleukin 6 in the diagnosis and follow-up of deep infiltrative endometriosis in women with chronic pelvic pain	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
JADE2 jade family PHD finger 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KDR kinase insert domain receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KRAS KRas proto-oncogene, GTPase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
LHCGR luteinizing hormone/choriogonadotropin receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MFHAS1 multifunctional ROCO family signaling regulator 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MLH1 mutL homolog 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MLLT10 MLLT10 histone lysine methyltransferase DOT1L cofactor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MPPED2 metallophosphoesterase domain containing 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MST1 macrophage stimulating 1	Molecular	Gene	—	—	Emerging	Open Targets	Ensembl Open Targets
MYH11 myosin heavy chain 11	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NEGR1 neuronal growth regulator 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NF1 neurofibromin 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NFE2L3 NFE2 like bZIP transcription factor 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NFILZ NFIL3 like basic leucine zipper	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NGF nerve growth factor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NOTCH1 notch receptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NOTCH2 notch receptor 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NR3C1 nuclear receptor subfamily 3 group C member 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NR3C2 nuclear receptor subfamily 3 group C member 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NUTM2B NUT family member 2B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Number of Participants with Pregnancy	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Number of participants with maximum severity of TEAEs (Part A)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
OPRK1 opioid receptor kappa 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
OPRM1 opioid receptor mu 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets

FDA-Approved Therapies

Phase 4 agents with regulatory approval for this indication

Drug Name	Mechanism	Type
3,3',4',5-TETRACHLOROSALICYLANILIDE		Gene-targeted
ABIRATERONE ACETATE	inhibitor	Gene-targeted
ACETAZOLAMIDE	None	Gene-targeted
ACETOPHENAZINE		Gene-targeted
AFATINIB		Gene-targeted
ALCLOFENAC		Gene-targeted
ALCLOMETASONE DIPROPIONATE		Gene-targeted
AMCINONIDE		Gene-targeted
AMDINOCILLIN		Gene-targeted
AMIODARONE HYDROCHLORIDE		Gene-targeted
AMLEXANOX		Gene-targeted
AMLODIPINE BESYLATE		Gene-targeted
AMPHETAMINE	None	Gene-targeted
ANHYDROUS TACROLIMUS		Gene-targeted
APALUTAMIDE	inhibitor; inhibitor	Gene-targeted
APOMORPHINE		Gene-targeted
APREMILAST		Gene-targeted
ASTEMIZOLE		Gene-targeted
ATALUREN		Gene-targeted
ATEZOLIZUMAB		Gene-targeted
ATRACURIUM BESYLATE		Gene-targeted
ATROPINE		Gene-targeted
AZACITIDINE		Gene-targeted
AZARIBINE		Gene-targeted
BECLOMETHASONE DIPROPIONATE		Gene-targeted
BENAZEPRIL HYDROCHLORIDE		Gene-targeted
BENORILATE		Gene-targeted
BETAMETHASONE		Gene-targeted
BETAMETHASONE DIPROPIONATE		Gene-targeted
BETAMETHASONE SODIUM PHOSPHATE		Gene-targeted
BETAMETHASONE VALERATE		Gene-targeted
BICALUTAMIDE	inhibitor; inhibitor	Gene-targeted
BICALUTAMIDE	None	Gene-targeted
BIFONAZOLE		Gene-targeted
BISACODYL		Gene-targeted
BITHIONOL		Gene-targeted
BITHIONOLATE SODIUM		Gene-targeted
BORTEZOMIB		Gene-targeted
BROMOCRIPTINE		Gene-targeted
BROMOCRIPTINE MESYLATE		Gene-targeted

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, and merged ranking. Only agents with registry trials or published clinical literature are shown by default.

Show agents without direct trial evidence

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
3,3',4',5-TETRACHLOROSALICYLANILIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ABIRATERONE ACETATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ACETAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ACETOPHENAZINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AFATINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ALCLOFENAC Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ALCLOMETASONE DIPROPIONATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMCINONIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMDINOCILLIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMIODARONE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMLEXANOX Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMLODIPINE BESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMPHETAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ANHYDROUS TACROLIMUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
APALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
APOMORPHINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
APREMILAST Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ASTEMIZOLE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATALUREN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATEZOLIZUMAB Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
ATRACURIUM BESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATROPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AZACITIDINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AZARIBINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BECLOMETHASONE DIPROPIONATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BENAZEPRIL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BENORILATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BETAMETHASONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BETAMETHASONE DIPROPIONATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BETAMETHASONE SODIUM PHOSPHATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BETAMETHASONE VALERATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BICALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
BICALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BIFONAZOLE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BISACODYL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BITHIONOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BITHIONOLATE SODIUM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BORTEZOMIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BROMOCRIPTINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BROMOCRIPTINE MESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BUPRENORPHINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BUTAMBEN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
CAFFEINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CALCIFEDIOL ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CALCIPOTRIENE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CALCITRIOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CANDESARTAN CILEXETIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CANRENONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPIVASERTIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBACHOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Sources	Links
ASOPRISNIL	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
CANNABIDIOL	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
CHORIOGONADOTROPIN ALFA	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
CYPROTERONE ACETATE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
DEGARELIX	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
DYDROGESTERONE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
ELAGOLIX	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
ESKETAMINE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
ESTRADIOL	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
GONADORELIN	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
GONADORELIN ACETATE	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
GONADOTROPIN, CHORIONIC	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
INDOLE-3-CARBINOL	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
LEUPROLIDE	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
LEUPROLIDE ACETATE	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
LEVONORGESTREL	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
LINZAGOLIX	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
MENOTROPINS	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
NALTREXONE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
PENTOXIFYLLINE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
PROGESTERONE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
RELUGOLIX	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
SEGESTERONE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
SEGESTERONE ACETATE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
TRIPTORELIN	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
TRIPTORELIN ACETATE	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
TRIPTORELIN PAMOATE	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
ANASTROZOLE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
ASCORBIC ACID	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
ATOSIBAN	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
BENTAMAPIMOD	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
CABERGOLINE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
CETRORELIX	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
ELIAPIXANT	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
ESTROGEN	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
ESTROGENS, CONJUGATED	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
ETONOGESTREL	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
FILGRASTIM	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
GESTRINONE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
INFLIXIMAB	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
3,3',4',5-TETRACHLOROSALICYLANILIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ABIRATERONE ACETATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ACETAZOLAMIDE Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ACETOPHENAZINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
AFATINIB Repurposing via AKT1	Small molecule	Approved	Strong	95	—	DGIdb	—
ALCLOFENAC Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ALCLOMETASONE DIPROPIONATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMCINONIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
AMDINOCILLIN Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
AMIODARONE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMLEXANOX Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
AMLODIPINE BESYLATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMPHETAMINE Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ANHYDROUS TACROLIMUS Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
APALUTAMIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
APOMORPHINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
APREMILAST Repurposing via CDKN2B	Small molecule	Approved	Strong	95	—	DGIdb	—
ASTEMIZOLE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ATALUREN Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ATEZOLIZUMAB Repurposing via ARID1A	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
ATRACURIUM BESYLATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ATROPINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
AZACITIDINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
AZARIBINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BECLOMETHASONE DIPROPIONATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
BENAZEPRIL HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BENORILATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BETAMETHASONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
BETAMETHASONE DIPROPIONATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BETAMETHASONE SODIUM PHOSPHATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BETAMETHASONE VALERATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BICALUTAMIDE Repurposing via AR	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
BICALUTAMIDE Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BIFONAZOLE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
BISACODYL Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
BITHIONOL Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
BITHIONOLATE SODIUM Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BORTEZOMIB Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
BROMOCRIPTINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
BROMOCRIPTINE MESYLATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets

Natural Products

81 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked). Only agents with direct clinical evidence are shown by default.

Reference lookups: Examine.com

Show agents without direct trial evidence

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
Vitamin D3 Natural product Clinical trial publication Supplementation with vitamin D or ω-3 fatty acids in adolescent girls a… Meta Analysis, Review Dietary antioxidant supplementation seems to beneficially impact the se… Human Study Association between vitamin D and endometriosis among American women.	Nutraceutical	Approved	Moderate	20	4 trials 1 Trial pubs View evidence Registry trials NCT00654524 — Randomized Study of Gonadotropin-releasing-hormone Agonist (GnRH-a) or Expectant Management for Endometriosis (UNKNOWN) PHASE4 NCT02393482 — Psychological Impact of Amenorrhea in Women With Endometriosis (UNKNOWN) PHASE4 NCT06289257 — Analysis of Vitamin D and VDR Expression in Endometriosis: A Case-Control Study (COMPLETED) NCT02387931 — Supplementation in Adolescent Girls With Endometriosis (COMPLETED) PHASE4 Published literature Clinical trial publication Supplementation with vitamin D or ω-3 fatty acids in adolescent girls and young women with endometriosis (SAGE): a double-blind, randomized, placebo-controlled trial (The American journal of clinical nutrition, 2020) CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Omega-3 Fatty Acids Natural product Meta-analysis Effect of omega-3 polyunsaturated fatty acid on endometriosis Human Study Higher omega-3 fatty acid consumption is associated with a reduced risk… Human Study Supplementation with vitamin D or ω-3 fatty acids in adolescent girls a…	Nutraceutical	Approved	Moderate	20	1 trials 1 Meta-analysis View evidence Registry trials NCT02387931 — Supplementation in Adolescent Girls With Endometriosis (COMPLETED) PHASE4 Published literature Meta-analysis Effect of omega-3 polyunsaturated fatty acid on endometriosis (Clinics (Sao Paulo, Brazil), 2025) CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Vitamin D3 Natural product Clinical trial publication Supplementation with vitamin D or ω-3 fatty acids in adolescent girls a… Meta Analysis, Review Antioxidant vitamins supplementation reduce endometriosis related pelvi… Meta Analysis Vitamin C and E antioxidant supplementation may significantly reduce pa…	Nutraceutical	Approved	Emerging	19	4 trials 1 Trial pubs View evidence Registry trials NCT00654524 — Randomized Study of Gonadotropin-releasing-hormone Agonist (GnRH-a) or Expectant Management for Endometriosis (UNKNOWN) PHASE4 NCT02393482 — Psychological Impact of Amenorrhea in Women With Endometriosis (UNKNOWN) PHASE4 NCT06289257 — Analysis of Vitamin D and VDR Expression in Endometriosis: A Case-Control Study (COMPLETED) NCT02387931 — Supplementation in Adolescent Girls With Endometriosis (COMPLETED) PHASE4 Published literature Clinical trial publication Supplementation with vitamin D or ω-3 fatty acids in adolescent girls and young women with endometriosis (SAGE): a double-blind, randomized, placebo-controlled trial (The American journal of clinical nutrition, 2020) CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Melatonin Natural product Cochrane review Efficacy of antioxidant supplementation in alleviating endometriosis-re… Cochrane review Effect of melatonin for the management of endometriosis: A protocol of… Cochrane review Dietary supplements for dysmenorrhoea	Nutraceutical	Phase II	Moderate	17	2 trials 4 Cochrane 4 RCT View evidence Registry trials NCT03782740 — Effect of Melatonin on Reduction of Pelvic Pain (COMPLETED) PHASE2 NCT05298657 — The Angiotensin-Melatonin Axis in Poor and Hyper Responders for IVF Treatment (UNKNOWN) Published literature Cochrane review Efficacy of antioxidant supplementation in alleviating endometriosis-related pain: insights from a systematic review and meta-analysis of RCTs (Reproductive biology and endocrinology : RB&E, 2025) Cochrane review Effect of melatonin for the management of endometriosis: A protocol of systematic review and meta-analysis (Medicine, 2020) Cochrane review Dietary supplements for dysmenorrhoea (The Cochrane database of systematic reviews, 2016) Cochrane review Antioxidants for female subfertility (The Cochrane database of systematic reviews, 2013) Randomized controlled trial Melatonin and sleep parameters in infertile women with endometriosis: first results from the triple-blind randomized controlled trial of administration of melatonin in chronic pelvic pain and sleep disturbance (PloS one, 2025) Randomized controlled trial Adjuvant use of melatonin for pain management in endometriosis-associated pelvic pain-A randomized double-blinded, placebo-controlled trial (PloS one, 2023) Randomized controlled trial Adjuvant use of melatonin for pain management in dysmenorrhea - a randomized double-blinded, placebo-controlled trial (European journal of clinical pharmacology, 2022) Randomized controlled trial Efficacy of melatonin in the treatment of endometriosis: a phase II, randomized, double-blind, placebo-controlled trial (Pain, 2013) CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Omega-3 Fatty Acids Natural product Meta-analysis Effect of omega-3 polyunsaturated fatty acid on endometriosis Human Study Higher omega-3 fatty acid consumption is associated with a reduced risk… Human Study Supplementation with vitamin D or ω-3 fatty acids in adolescent girls a…	Nutraceutical	Approved	Emerging	13	1 trials 1 Meta-analysis View evidence Registry trials NCT02387931 — Supplementation in Adolescent Girls With Endometriosis (COMPLETED) PHASE4 Published literature Meta-analysis Effect of omega-3 polyunsaturated fatty acid on endometriosis (Clinics (Sao Paulo, Brazil), 2025) CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Melatonin Natural product Cochrane review Efficacy of antioxidant supplementation in alleviating endometriosis-re… Cochrane review Effect of melatonin for the management of endometriosis: A protocol of… Cochrane review Dietary supplements for dysmenorrhoea	Nutraceutical	Phase II	Emerging	13	2 trials 4 Cochrane 4 RCT View evidence Registry trials NCT03782740 — Effect of Melatonin on Reduction of Pelvic Pain (COMPLETED) PHASE2 NCT05298657 — The Angiotensin-Melatonin Axis in Poor and Hyper Responders for IVF Treatment (UNKNOWN) Published literature Cochrane review Efficacy of antioxidant supplementation in alleviating endometriosis-related pain: insights from a systematic review and meta-analysis of RCTs (Reproductive biology and endocrinology : RB&E, 2025) Cochrane review Effect of melatonin for the management of endometriosis: A protocol of systematic review and meta-analysis (Medicine, 2020) Cochrane review Dietary supplements for dysmenorrhoea (The Cochrane database of systematic reviews, 2016) Cochrane review Antioxidants for female subfertility (The Cochrane database of systematic reviews, 2013) Randomized controlled trial Melatonin and sleep parameters in infertile women with endometriosis: first results from the triple-blind randomized controlled trial of administration of melatonin in chronic pelvic pain and sleep disturbance (PloS one, 2025) Randomized controlled trial Adjuvant use of melatonin for pain management in endometriosis-associated pelvic pain-A randomized double-blinded, placebo-controlled trial (PloS one, 2023) Randomized controlled trial Adjuvant use of melatonin for pain management in dysmenorrhea - a randomized double-blinded, placebo-controlled trial (European journal of clinical pharmacology, 2022) Randomized controlled trial Efficacy of melatonin in the treatment of endometriosis: a phase II, randomized, double-blind, placebo-controlled trial (Pain, 2013) CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Vitamin C Natural product Meta Analysis, Review Antioxidant vitamins supplementation reduce endometriosis related pelvi… Meta Analysis Vitamin C and E antioxidant supplementation may significantly reduce pa… Human Study Antioxidant supplementation reduces endometriosis-related pelvic pain i…	Nutraceutical	Preclinical	Emerging	10	4 RCT View evidence CT.gov search · Cochrane · PubMed		PubChem
Vitamin E Natural product Clinical trial publication The Effect of Combined Vitamin C and Vitamin E Supplementation on Oxida… Clinical trial publication Antioxidant supplementation reduces endometriosis-related pelvic pain i… Clinical trial publication Women with endometriosis improved their peripheral antioxidant markers…	Nutraceutical	Phase II	Emerging	10	1 trials 4 Meta-analysis 4 Trial pubs View evidence Registry trials NCT02058212 — Use of Antioxidant in Endometriotic Women to Improve Intracytoplasmic Sperm Injection (ICSI) (COMPLETED) PHASE2 Published literature Clinical trial publication The Effect of Combined Vitamin C and Vitamin E Supplementation on Oxidative Stress Markers in Women with Endometriosis: A Randomized, Triple-Blind Placebo-Controlled Clinical Trial (Pain research & management, 2021) Clinical trial publication Antioxidant supplementation reduces endometriosis-related pelvic pain in humans (Translational research : the journal of laboratory and clinical medicine, 2013) Clinical trial publication Women with endometriosis improved their peripheral antioxidant markers after the application of a high antioxidant diet (Reproductive biology and endocrinology : RB&E, 2009) Clinical trial publication Lipid peroxidation and vitamin E in serum and follicular fluid of infertile women with peritoneal endometriosis submitted to controlled ovarian hyperstimulation: a pilot study (Fertility and sterility, 2008) CT.gov search · Cochrane · PubMed		PubChem
N-Acetylcysteine Natural product Clinical trial publication Administration of N-acetylcysteine influence the expression of apoptoti… Clinical trial publication Comparing the effect of adjunctive N-acetylcysteine plus low dose contr… Human Study Oral NAC improves endometriosis-related pain and the size of endometrio…	Amino acid	Phase III	Emerging	10	1 trials 2 Trial pubs View evidence Registry trials NCT05460858 — NAC Effect on Infertile Women With Endometrioma (UNKNOWN) PHASE3 Published literature Clinical trial publication Administration of N-acetylcysteine influence the expression of apoptotic genes in the granulosa cells of infertile women diagnosed with endometriosis (Scientific reports, 2026) Clinical trial publication Comparing the effect of adjunctive N-acetylcysteine plus low dose contraceptive with low dose contraceptive alone on recurrence of ovarian endometrioma and chronic pelvic pain after conservative laparoscopic surgery: a randomised clinical trial study (Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2022) CT.gov search · Cochrane · PubMed		PubChem
Zinc Natural product Human Study Deficient intake of antioxidants is associated with an intensification… Review A review of dietary supplements for treatment of endometriosis.	Nutraceutical	Phase II	Emerging	10	1 trials 1 Trial pubs View evidence Registry trials NCT02058212 — Use of Antioxidant in Endometriotic Women to Improve Intracytoplasmic Sperm Injection (ICSI) (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed		PubChem
Ginger Natural product Cochrane review Dietary supplements for dysmenorrhoea Review Mechanistic insights into the anti-inflammatory and anti-proliferative… Review Nutritional implications of ginger: chemistry, biological activities an…	Botanical	Preclinical	Emerging	10	1 Cochrane View evidence Published literature Cochrane review Dietary supplements for dysmenorrhoea (The Cochrane database of systematic reviews, 2016) CT.gov search · Cochrane · PubMed		PubChem
Vitamin K Natural product Meta Analysis, Review Antioxidant vitamins supplementation reduce endometriosis related pelvi… Meta Analysis, Review Dietary antioxidant supplementation seems to beneficially impact the se… Meta Analysis Vitamin C and E antioxidant supplementation may significantly reduce pa…	Nutraceutical	Preclinical	Emerging	10	No indexed hits View evidence CT.gov search · Cochrane · PubMed		PubChem
Resveratrol Natural product Human Study Resveratrol lowers VEGF and TNF-α 2 expression in endometriosis women. Animal Study Regression of endometrial implants by resveratrol in an experimentally… Animal Study Resveratrol alone is a potential agent for the treatment of endometrios…	Food compound	Approved	Emerging	7	1 trials View evidence Registry trials NCT02475564 — Resveratrol for Pain Due to Endometriosis (COMPLETED) PHASE4 CT.gov search · Cochrane · PubMed		PubChem
Curcumin Natural product Human Study Nanomicelle curcumin improves oxidative stress, inflammatory markers, a… Animal Study Curcumin exhibits potentially therapeutic properties in a rat experimen… Animal Study Curcumin treats endometriosis in mice by the HIF signaling pathway.	Food compound	Preclinical	Emerging	7	2 trials 3 Trial pubs 3 RCT View evidence Registry trials NCT03016039 — Curcumin Supplementation for Gynecological Diseases (UNKNOWN) NA NCT04150406 — Flexofytol® for the Treatment of Endometriosis- Associated Pain (UNKNOWN) NA CT.gov search · Cochrane · PubMed		PubChem
Quercetin Natural product Systematic review Impact of curcumin, quercetin, or resveratrol on the pathophysiology of… Animal Study, In Vitro Study Effectiveness of the integration of quercetin, turmeric, and N-acetylcy… Animal Study Flavonoids quercetin and kaempferol are NR4A1 antagonists and suppress…	Food compound	Preclinical	Emerging	7	1 trials View evidence Registry trials NCT05983224 — Effect of Quercetin Supplementation on Endometriosis Outcomes (UNKNOWN) NA Published literature Systematic review Impact of curcumin, quercetin, or resveratrol on the pathophysiology of endometriosis: A systematic review (Phytotherapy research : PTR, 2022) CT.gov search · Cochrane · PubMed		PubChem
Feverfew Natural product Animal Study Parthenolide reduces cell proliferation and prostaglandin E2 [corrected… Animal Study Parthenolide repressed endometriosis. Review Plants as source of new therapies for endometriosis: a review of precli…	Botanical	Preclinical	Emerging	7	No indexed hits View evidence CT.gov search · Cochrane · PubMed		PubChem
Boswellia Natural product Animal Study, In Vitro Study Frankincense ameliorates endometriosis via inducing apoptosis and reduc… Animal Study Regulation of apoptosis and oxidative stress by oral Boswellia serrata… In Vitro Study A botanical extract inhibits cell proliferation, induces apoptosis, and…	Botanical	Preclinical	Emerging	7	2 pubs View evidence CT.gov search · Cochrane · PubMed		PubChem
Egcg Natural product Animal Study Anti-angiogenic effects of green tea catechin on an experimental endome… Animal Study Tea polyphenols inhibit the growth and virulence properties of Fusobact…	Food compound	Phase II	Emerging	7	1 trials View evidence Registry trials NCT02832271 — Green Tea Extract for Endometriosis Treatment (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed		PubChem
Alpha-Lipoic Acid Natural product Systematic review The role of alpha lipoic acid in female and male infertility: a systema… Animal Study Alpha-linolenic acid regulates the gut microbiota and the inflammatory… Animal Study Sinomenine can inhibit the production and activity of TNF-alpha and NF-…	Nutraceutical	Preclinical	Emerging	7	2 Cochrane View evidence Published literature Systematic review The role of alpha lipoic acid in female and male infertility: a systematic review (Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2021) CT.gov search · Cochrane · PubMed		PubChem
Probiotics Natural product Review A review of dietary supplements for treatment of endometriosis. Review Gut microbiota and endometriosis: exploring the relationship and therap…	Probiotic	Phase II	Emerging	7	4 trials 3 RCT View evidence Registry trials NCT07149519 — Impact of Dietary Guidance and Probiotics in the Treatment of Endometriosis and Irritable Bowel Syndrome in Women (RECRUITING) NA NCT06929364 — The Role of Probiotics in the Treatment of Endometriosis (ProMetrioS): a Randomised Double-blinded Placebo-controlled Cross-over Trial (RECRUITING) NA NCT06592976 — Effects of a Multi-strain Oral Probiotic on the Vaginal Microbiota Composition in Healthy Women and Women with Endometriosis (ACTIVE_NOT_RECRUITING) NA NCT04955574 — Probiotic and Antibiotic Therapies in Women With Unexplained Infertility (WITHDRAWN) PHASE2 CT.gov search · Cochrane · PubMed		—
Selenium Natural product Human Study Deficient intake of antioxidants is associated with an intensification…	Nutraceutical	Preclinical	Emerging	7	—		PubChem
Silymarin Natural product Human Study Silymarin significantly reduced interleukin-6 levels, sizes of endometr…	Botanical	Preclinical	Emerging	7	—		PubChem
Sulforaphane Natural product Animal Study Sulforaphane exhibits antiproliferative, apoptotic, anti-inflammatory,…	Food compound	Preclinical	Emerging	7	—		PubChem
Licorice Natural product In Vitro Study A botanical extract inhibits cell proliferation, induces apoptosis, and… Review Mechanistic insights into the anti-inflammatory and anti-proliferative…	Botanical	Preclinical	Emerging	2	—		—
EGCG (Epigallocatechin Gallate) Natural product Animal Study Anti-angiogenic effects of green tea catechin on an experimental endome… Animal Study Tea polyphenols inhibit the growth and virulence properties of Fusobact… Review A review of dietary supplements for treatment of endometriosis.	Nutraceutical	Preclinical	Emerging	0	—		—
Polyphenols Natural product Animal Study Fisetin ameliorates endometriosis modulating mast cells derived NLRP-3… Animal Study Tea polyphenols inhibit the growth and virulence properties of Fusobact… Animal Study The effect of Rubus idaeus polyphenols extract in induced endometriosis.	Nutraceutical	Preclinical	Emerging	0	—		—
Ginsenosides Natural product Animal Study Ginsenoside Rf alleviates dysmenorrhea and inflammation in a model of e… Animal Study, In Vitro Study Ginsenoside Rg3 decreases fibrotic and invasive nature of endometriosis. Animal Study Ginsenoside Rg3 suppresses angiogenesis in developing endometrial lesio…	Nutraceutical	Preclinical	Emerging	0	—		—
Flavonoids Natural product Animal Study Flavonoids quercetin and kaempferol are NR4A1 antagonists and suppress… Animal Study The regression of endometriosis with glycosylated flavonoids isolated f… Animal Study Xanthohumol inhibits growth and vascularization of developing endometri…	Nutraceutical	Preclinical	Emerging	0	—		—
Vitamin a Natural product Meta Analysis, Review Antioxidant vitamins supplementation reduce endometriosis related pelvi… Human Study Women with endometriosis improved their peripheral antioxidant markers… Meta Analysis, Review Dietary antioxidant supplementation seems to beneficially impact the se…	Food compound	Preclinical	Emerging	0	—		PubChem
Xanthohumol Natural product Animal Study Xanthohumol inhibits growth and vascularization of developing endometri… Review Plants as source of new therapies for endometriosis: a review of precli… Review Selected antioxidants could be used to treat endometriosis by reducing…	Nutraceutical	Preclinical	Emerging	0	—		—
Fruit: All Natural product Human Study A higher intake of fruits is associated with a lower risk of endometrio…	Nutraceutical	Preclinical	Emerging	0	—		—
Vegetables: All Natural product Human Study A higher intake of fruits is associated with a lower risk of endometrio…	Nutraceutical	Preclinical	Emerging	0	—		—
Astaxanthin Natural product Human Study Astaxanthin ameliorates inflammation, oxidative stress, and reproductiv… Review Elevated levels of ROS and free radicals are involved in the pathogenes…	Food compound	Preclinical	Emerging	0	—		PubChem
Antioxidant Formulas Natural product Human Study Deficient intake of antioxidants is associated with an intensification… Human Study Women with endometriosis improved their peripheral antioxidant markers… Meta Analysis, Review Antioxidant vitamins supplementation reduce endometriosis related pelvi…	Nutraceutical	Preclinical	Emerging	0	—		—
Progesterone Natural product Human Study Low levels of progesterone in the follicular phase could be responsible… In Vitro Study Progesterone inhibits cytokine-induced interleukein-6 production associ…	Food compound	Preclinical	Emerging	0	—		PubChem
Garlic: Aged Natural product Human In Vitro These results suggest that HEABG may be effective in the prevention and… Review Aged garlic extract as a potential prophylactic to reduce the progressi…	Nutraceutical	Preclinical	Emerging	0	—		—
Nettle Natural product Animal Study The aerial parts of U. dioica exhibited promising activity in the endom…	Nutraceutical	Preclinical	Emerging	0	—		—
Genistein Natural product Animal Study This study concluded that genistein prevented endometriosis by performi… In Vitro Study Genistein can be a candidate in the treatment of endometriosis.	Food compound	Preclinical	Emerging	0	—		PubChem
Apigenin Natural product Review Anti-infertility roles of flavonoids: insights into the female reproduc… Review Plants as source of new therapies for endometriosis: a review of precli…	Food compound	Preclinical	Emerging	0	—		PubChem
Catechin Natural product Animal Study Anti-angiogenic effects of green tea catechin on an experimental endome… Review Antifibrotic properties of epigallocatechin-3-gallate in endometriosis. Review Natural therapies assessment for the treatment of endometriosis.	Nutraceutical	Preclinical	Emerging	0	—		—
Naringenin Natural product In Vitro Study Naringenin is a promising therapeutic compound for treatment of endomet… In Vitro Study naringenin may have a therapeutic potential in the treatment of endomet…	Food compound	Preclinical	Emerging	0	—		PubChem
Pterostilbene Natural product In Vitro Study Natural resveratrol analogs differentially target endometriotic cells i… In Vitro Study Resveratrol and its natural analogs mitigate immune dysregulation and o…	Nutraceutical	Preclinical	Emerging	0	—		—
Puerarin Natural product Review Plants as source of new therapies for endometriosis: a review of precli… In Vitro Study Puerarin suppresses invasion and vascularization of endometriosis tissu…	Nutraceutical	Preclinical	Emerging	0	—		—
Cryptoxanthin Natural product Human Study A higher intake of fruits is associated with a lower risk of endometrio…	Nutraceutical	Preclinical	Emerging	0	—		—
Emodin Natural product Human In Vitro, Human Study Emodin inhibits the migration and invasion abilities of human endometri…	Nutraceutical	Preclinical	Emerging	0	—		—
Homeopathic Medicine: All Natural product Human Study Potentized estrogen at a dose of 3 drops twice daily for 24 weeks was e… Human Study Chinese herbal medicine has therapeutic value in the treatment of endom… Review A review of plant-derived medicines for treatment of endometriosis.	Nutraceutical	Preclinical	Emerging	0	—		—
Ginseng (Siberian) Natural product Human In Vitro Saponin extracts induced apoptosis of endometrial cells from women with…	Nutraceutical	Preclinical	Emerging	0	—		—
Formononetin Natural product Animal Study, In Vitro Study Formononetin inhibits progression of endometriosis.	Nutraceutical	Preclinical	Emerging	0	—		—
6-Shogaol Natural product Animal Study 6-Shogaol reduces progression of experimental endometriosis.	Nutraceutical	Preclinical	Emerging	0	—		—
Acai Natural product Animal Study Açaí is a promising novel pharmacological therapeutic treatment for end…	Nutraceutical	Preclinical	Emerging	0	—		—
Aloe Vera Natural product Animal Study Aloe vera is effective in the inhibition of formation and regression of…	Nutraceutical	Preclinical	Emerging	0	—		—
Luteolin Natural product Animal Study, In Vitro Study Ameliorative effects of luteolin against endometriosis progression.	Food compound	Preclinical	Emerging	0	—		PubChem
Bufalin Natural product Animal Study, In Vitro Study Bufalin suppresses endometriosis progression by inducing pyroptosis and…	Nutraceutical	Preclinical	Emerging	0	—		—
Bee Propolis Natural product Animal Study Caffeic acid phenethyl ester, a compound found within propolis causes r… Animal Study Sulawesi propolis induces higher apoptotic activity and lower inflammat…	Nutraceutical	Preclinical	Emerging	0	—		—
Caffeic Acid Phenethyl Ester Natural product Human Study Low levels of progesterone in the follicular phase could be responsible… Human Study Vitamin D intake in patients with endometriosis resulted in a significa… Animal Study Caffeic acid phenethyl ester, a compound found within propolis causes r…	Food compound	Preclinical	Emerging	0	—		PubChem
Cat's Claw Natural product Animal Study Cat's claw extract appears to be a promising alternative for treat…	Nutraceutical	Preclinical	Emerging	0	—		—
Hesperidin Natural product Animal Study Effects of quince gel and hesperidin mixture on experimental endometrio…	Food compound	Preclinical	Emerging	0	—		PubChem
Fisetin Natural product Animal Study Fisetin ameliorates endometriosis modulating mast cells derived NLRP-3…	Food compound	Preclinical	Emerging	0	—		PubChem
Kaempferol Natural product Animal Study Flavonoids quercetin and kaempferol are NR4A1 antagonists and suppress…	Food compound	Preclinical	Emerging	0	—		PubChem
Fucoidan Natural product Animal Study, In Vitro Study Fucoidan can effectively inhibit cell proliferation and cell migration…	Nutraceutical	Preclinical	Emerging	0	—		—
Honokiol Natural product Animal Study Honokiol effectively inhibit the proliferation of rat edometeriotic tis…	Nutraceutical	Preclinical	Emerging	0	—		—
Indole-3-Carbinol Natural product Animal Study Indole-3-carbinol inhibits the growth of endometriotic lesions.	Nutraceutical	Preclinical	Emerging	0	—		—
Leonurine Natural product Animal Study Leonurine attenuates hyperalgesia in mMice with induced adenomyosis.	Nutraceutical	Preclinical	Emerging	0	—		—
Myricetin Natural product Animal Study, In Vitro Study Myricetin has antiproliferative effects on endometriosis through cell c…	Food compound	Preclinical	Emerging	0	—		PubChem
Oleuropein Natural product Animal Study Oleuropein suppresses endometriosis progression and improves the fertil…	Nutraceutical	Preclinical	Emerging	0	—		—
Palmitoylethanolamide Natural product Animal Study Palmitoylethanolamide and polydatin treatment causes endometriotic lesi…	Nutraceutical	Preclinical	Emerging	0	—		—
Royal Jelly Natural product Animal Study Possible therapeutic effect of royal jelly on endometriotic lesion size…	Nutraceutical	Preclinical	Emerging	0	—		—
Sea Buckthorn Natural product Animal Study Sea buckthorn and St. John's wort oil may be a promising alternati…	Nutraceutical	Preclinical	Emerging	0	—		—
St. John's Wort Natural product Animal Study Sea buckthorn and St. John's wort oil may be a promising alternati…	Botanical	Preclinical	Emerging	0	—		PubChem
Silibinin Natural product Animal Study Silibinin-induced endoplasmic reticulum stress and mitochondrial dysfun…	Nutraceutical	Preclinical	Emerging	0	—		—
Sinomenine Natural product Animal Study Sinomenine can inhibit the production and activity of TNF-alpha and NF-…	Nutraceutical	Preclinical	Emerging	0	—		—
Propolis: Bee Natural product Animal Study Caffeic acid phenethyl ester, a compound found within propolis causes r… Animal Study Sulawesi propolis induces higher apoptotic activity and lower inflammat…	Nutraceutical	Preclinical	Emerging	0	—		—
Broccoli Sprouts Natural product Animal Study Sulforaphane exhibits antiproliferative, apoptotic, anti-inflammatory,…	Nutraceutical	Preclinical	Emerging	0	—		—
Black Tea Natural product Animal Study Tea polyphenols inhibit the growth and virulence properties of Fusobact…	Nutraceutical	Preclinical	Emerging	0	—		—
Theaflavins Natural product Animal Study Tea polyphenols inhibit the growth and virulence properties of Fusobact…	Nutraceutical	Preclinical	Emerging	0	—		—
Raspberry Natural product Animal Study The effect of Rubus idaeus polyphenols extract in induced endometriosis.	Nutraceutical	Preclinical	Emerging	0	—		—
Yellow Sweet Clover (Melilotus Officinalis) Natural product Animal Study The regression of endometriosis with glycosylated flavonoids isolated f…	Nutraceutical	Preclinical	Emerging	0	—		—
Hydrogen: Molecular Natural product Animal Study The results showed that both profiles of high-dose H2 breathing reduced… Review Review of the potential therapeutic effects and molecular mechanisms of…	Nutraceutical	Preclinical	Emerging	0	—		—
Nobiletin Natural product Animal Study This study provides the first evidence that nobiletin exert protection…	Nutraceutical	Preclinical	Emerging	0	—		—
Vanillin Natural product Animal Study Vanillin prevents the growth of endometriotic lesions through anti-infl…	Nutraceutical	Preclinical	Emerging	0	—		—

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.